International Recognition and Reliance Pathways: The UK’s New Model for Device Access

Multi-market regulatory strategy has traditionally meant building parallel, largely independent submission packages for each jurisdiction — even when the underlying clinical and technical evidence is identical. The UK’s draft International Reliance framework, published in 2026, is one of the clearest signals yet that major regulators are moving toward genuine reliance on each other’s decisions rather than duplicating review from scratch. For sponsors with US approvals already in hand, it’s a development worth building into market-entry planning now, even though it isn’t yet operational.

What the UK Is Actually Proposing

On May 8, 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) published draft Medical Devices (Amendment) Regulations 2026 on the World Trade Organization notification portal — described as the most significant overhaul of the Great Britain device framework since Brexit. The centerpiece is a new International Reliance pathway that would sit alongside the existing UKCA and CE marking routes as a third pillar of market access.

The framework designates three “Comparable Regulator Countries” (CRCs) whose device approvals can support reliance-based UK market entry: the United States (FDA, across 510(k), De Novo, and PMA pathways), Canada (Health Canada’s Medical Device Regulations), and Australia (the Therapeutic Goods Administration). Devices approved through these regulators would be eligible for a reliance route offering abridged assessment rather than a full independent UK review — built on WHO Good Reliance Practices designed to reduce duplication and speed patient access.

Notably, the EU is not included as a CRC. CE-marked devices continue to be accepted in Great Britain under separate transitional arrangements — until June 2028 for most devices, or June 2030 for devices compliant with EU MDR or IVDR — but the MHRA deferred implementing a distinct reliance route for CE-marked products after strong consultee demand for indefinite recognition, and is conducting further consultation on that question separately.

What Reliance Does and Doesn’t Mean in Practice

Reliance is not automatic acceptance. Devices entering Great Britain through the international reliance route will still need to satisfy UK-specific requirements: English-language labeling and packaging, assignment of a unique device identifier, and appointment of a UK Responsible Person. The pathway is described as an “abridged assessment” — meaning FDA, TGA, or Health Canada approval substantially reduces the review burden, but doesn’t eliminate UK-specific compliance obligations.

Certain product categories are also carved out. Custom-made or in-house devices are excluded, as are certain SaMD and AI-enabled device (AIaMD) products — particularly those depending on predicate equivalence rather than independent clinical evidence — along with non-well-established-technology Class IIb/III devices approved via 510(k), and companion diagnostics tied to medicines not separately licensed in the UK. This matters significantly for AI/ML-heavy device portfolios: sponsors shouldn’t assume reliance automatically extends to their most software-driven products.

The FDA-MHRA Relationship Specifically

Beyond the general CRC framework, FDA and MHRA have been building a more direct bilateral relationship. On April 7, 2026, the two agencies announced strengthened regulatory cooperation on medical devices, building on an October 2025 collaboration announcement, with a stated commitment to exploring closer regulatory alignment and potential mutual recognition mechanisms specifically between the US and UK systems. As of this announcement, this remains a framework commitment for technical work rather than an operational agreement — no specific recognition routes have been confirmed — but it’s a concrete signal for manufacturers with dual UK-US market strategies about the direction both agencies are heading.

Timeline

The draft regulations were opened for a WTO stakeholder call for evidence beginning May 11, 2026, with the consultation period running through June 19, 2026. The MHRA has also launched a parallel stakeholder impact survey to inform its formal impact assessment. Adoption is anticipated in late 2026, with reliance routes for FDA, TGA, and Health Canada-approved devices expected to become active from 2027.

What Sponsors Should Do Now — Even Before This Is Final

Sequence market entry strategy around CRC status. Sponsors planning US approval followed by UK entry should factor the emerging reliance pathway into timeline planning now — a device cleared via 510(k), De Novo, or PMA today may be positioned to leverage an abridged UK assessment once the pathway becomes operational in 2027, rather than requiring a fully independent UK submission built from scratch.

Don’t assume AI/SaMD products are automatically covered. Given the explicit carve-outs for certain AIaMD and predicate-equivalence-dependent SaMD, sponsors in this category should track the final regulations closely rather than assuming reliance applies uniformly across their portfolio.

Watch the CE-mark reliance question separately. For sponsors with EU-only regulatory strategies, the deferred consultation on indefinite CE-mark recognition is arguably more consequential than the CRC framework — it determines whether a fourth, EU-based pathway into Great Britain persists long-term or narrows to the 2028/2030 transitional deadlines.

Recognize this as part of a broader global trend, not a one-off UK reform. The UK’s move follows a broader direction among regulators — reducing duplicative independent review where a trusted counterpart regulator has already conducted rigorous assessment — and sponsors building long-term multi-market strategy should expect more jurisdictions to formalize similar reliance mechanisms over time.

International reliance frameworks won’t replace the need for jurisdiction-specific regulatory expertise — UK-specific labeling, post-market surveillance, and Responsible Person obligations remain real work. But for sponsors with strong US, Canadian, or Australian approval histories, the emerging model represents a genuine reduction in the cost and timeline of expanding into new markets, and it’s worth building into 2027 planning now.

This article reflects the UK’s draft Medical Devices (Amendment) Regulations 2026 as published for consultation and is current as of mid-2026. The framework remains subject to change through the consultation and adoption process. This is intended for general regulatory and educational purposes and does not constitute regulatory or legal advice for a specific product or market strategy.